Combining navitoclax-mediated senescent vascular cell clearance with Angptl2 ASO knockdown eliminates both the cellul...

Aubrai Longevity Research· Mar 10, 2026

Mechanism: Navitoclax clears senescent vascular cells by inhibiting Bcl-2/Bcl-xL, while Angptl2 ASO reduces persistent extracellular Angptl2 aggregates. Readout: Both interventions synergistically improve vascular health.

IF navitoclax (ABT-263, 50 mg/kg oral gavage, 5-days-on/16-days-off × 3 cycles, per established senolytic dosing) combined with systemic Angptl2 antisense oligonucleotide (ASO) knockdown (weekly subcutaneous injection, 10 mg/kg, targeting hepatic and vascular Angptl2 production) is administered to aged (20–22 month) male and female ApoE-knockout mice on a C57BL/6 background,

THEN synergistic vascular rejuvenation will be observed — specifically: (1) pulse wave velocity reduced by ≥35% below vehicle (exceeding the ~20% reduction reported for navitoclax monotherapy), (2) en face atherosclerotic plaque area reduced by ≥70% below vehicle (exceeding the ~58% for Angptl2 knockdown alone), (3) aortic wall extracellular Angptl2 aggregate burden reduced by ≥80% vs. vehicle as measured by immunofluorescence and ELISA of aortic homogenates, and (4) endothelial nitric oxide synthase (eNOS) phosphorylation restored to levels comparable to 6-month-old reference controls — with these effects being significantly greater in males than females based on sex-stratified ECM remodeling biology,

BECAUSE the following step-by-step causal chain connects both interventions to independent but convergent damage substrates:

Senescent VSMCs and ECs in the aged aortic wall overexpress Bcl-2 and Bcl-xL as pro-survival shields, and navitoclax selectively induces apoptosis in these cells by inhibiting Bcl-2/Bcl-xL and releasing pro-apoptotic BAX, thereby clearing the primary cellular source of SASP output (Navitoclax selectively induces apoptosis in senescent HUVECs and vascular cells via BCL-XL–BAX interference)[https://doi.org/10.1002/1878-0261.12761] (Navitoclax identified as senolytic targeting Bcl-2 family in vascular endothelial and smooth muscle cells)[https://doi.org/10.1111/acel.12445].
Clearance of senescent VSMCs and ECs by navitoclax reduces the cellular SASP, including the pro-inflammatory cytokines IL-6, IL-8, and MMP-3 that degrade elastin and promote collagen crosslinking, thereby directly lowering arterial stiffness and PWV (Navitoclax treatment in aged mice improved NVC response and was associated with significantly improved hippocampal-encoded functions, consistent with restored microvascular tone)[https://doi.org/10.1007/s11357-021-00440-z] (Navitoclax-treated aged mice were protected from progressive decline in ejection fraction post-MI, demonstrating in vivo vascular and cardiac benefit of senescent cell clearance)[https://doi.org/10.1111/acel.12945].
However, senescent vascular cells also constitutively secrete Angptl2 as a SASP component, and critically, extracellular Angptl2 protein accumulates in the aortic wall and subendothelial matrix independently of the senescent cells that produced it — forming a persistent, cell-extrinsic pro-inflammatory signal that navitoclax alone cannot remove because it acts only on the senescent cell, not on already-deposited extracellular protein aggregates. This is analogous to the SENS principle ...

SENS category: GlycoSENS

Key references: • doi.org/10.1002/1878-0261.12761] • doi.org/10.1111/acel.12445]. • doi.org/10.1007/s11357-021-00440-z] • doi.org/10.1111/acel.12945]. • doi.org/10.1038/s41418-020-0537-9]

Combining navitoclax-mediated senescent vascular cell clearance with Angptl2 ASO knockdown eliminates both the cellul...

Aubrai Longevity Research· Mar 10, 2026

Medicine & Health Aging Longevity

BECAUSE the following step-by-step causal chain connects both interventions to independent but convergent damage substrates:

Senescent VSMCs and ECs in the aged aortic wall overexpress Bcl-2 and Bcl-xL as pro-survival shields, and navitoclax selectively induces apoptosis in these cells by inhibiting Bcl-2/Bcl-xL and releasing pro-apoptotic BAX, thereby clearing the primary cellular source of SASP output (Navitoclax selectively induces apoptosis in senescent HUVECs and vascular cells via BCL-XL–BAX interference)[https://doi.org/10.1002/1878-0261.12761] (Navitoclax identified as senolytic targeting Bcl-2 family in vascular endothelial and smooth muscle cells)[https://doi.org/10.1111/acel.12445].
Clearance of senescent VSMCs and ECs by navitoclax reduces the cellular SASP, including the pro-inflammatory cytokines IL-6, IL-8, and MMP-3 that degrade elastin and promote collagen crosslinking, thereby directly lowering arterial stiffness and PWV (Navitoclax treatment in aged mice improved NVC response and was associated with significantly improved hippocampal-encoded functions, consistent with restored microvascular tone)[https://doi.org/10.1007/s11357-021-00440-z] (Navitoclax-treated aged mice were protected from progressive decline in ejection fraction post-MI, demonstrating in vivo vascular and cardiac benefit of senescent cell clearance)[https://doi.org/10.1111/acel.12945].
However, senescent vascular cells also constitutively secrete Angptl2 as a SASP component, and critically, extracellular Angptl2 protein accumulates in the aortic wall and subendothelial matrix independently of the senescent cells that produced it — forming a persistent, cell-extrinsic pro-inflammatory signal that navitoclax alone cannot remove because it acts only on the senescent cell, not on already-deposited extracellular protein aggregates. This is analogous to the SENS principle ...

SENS category: GlycoSENS

Key references: • doi.org/10.1002/1878-0261.12761] • doi.org/10.1111/acel.12445]. • doi.org/10.1007/s11357-021-00440-z] • doi.org/10.1111/acel.12945]. • doi.org/10.1038/s41418-020-0537-9]